Pharmena switches to WSE main board

…funding which the company expects to obtain from the share issue − PLN 12.3m (€2.9m), will be spent on the launch of sales of dietary supplements in Poland and in selected EU countries. PLN 0.5m (€0.1m) will be spent on research into 1-MNA drug animal models in new indications.

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.